Your Article Summary
See Latest ArticlesA Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Clinical Cancer Research, 06/25/09
Goel S et al. - Eribulin mesylate, given on days 1, 8, and 15 of a 28-day cycle, exhibits manageable tolerability at 1.0 mg/m2 with further dose escalation limited by neutropenia and fatigue.
Related Articles
Musculoskeletal manifestations in patients with malignant disease
Clinical Rheumatology, 11/16/09
Relevance Score: 65%
Diagnosis and Management of Adnexal Masses
American Family Physician, 10/16/09
Relevance Score: 65%
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas
Cancer Chemotherapy and Pharmacology, 11/12/09
Relevance Score: 64%
Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of solid pancreatic masses: the impact on patient-management strategy
Alimentary Pharmacology and Therapeutics, 10/23/09
Relevance Score: 64%
A Phase I and Pharmacokinetic Study of Oral Lapatinib Administered Once or Twice Daily in Patients with Solid Malignancies
Clinical Cancer Research, 10/15/09
Relevance Score: 64%
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves Newly Revised Prescribing Information For Azilect Reducing Medication And Food Restrictions
Teva Pharmaceutical Industries, 12/15/09
Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia
Current Medical Research and Opinion, 12/14/09
Salmeterol/fluticasone propionate vs. double dose fluticasone propionate on lung function and asthma control in children
Pediatric Allergy and Immunology, 12/14/09